上海莱士血液制品股份有限公司 关于收购南岳生物制药有限公司100%股权进展 暨完成工商变更登记的公告

Group 1 - The company Shanghai Laishi Blood Products Co., Ltd. signed an equity transfer agreement to acquire 100% equity of Nanyue Biological Pharmaceutical Co., Ltd. on March 26, 2025 [2] - The total consideration for the transaction is divided into a base consideration of 4.2 billion yuan and a contingent consideration of 50 million yuan if the company's plasma collection reaches 305 tons in 2025 [4] - The funding for the transaction will come from the company's own funds and self-raised funds [3] Group 2 - Nanyue Biological has completed the necessary business registration changes and obtained a new business license from the market supervision administration [5] - The company now holds 100% equity of Nanyue Biological, which has become a wholly-owned subsidiary, and will actively promote its daily operations and key projects [6]